InnerCap Tech Inc v. Natals Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: InnerCap Technologies, Inc. (Florida)
  • Defendant: Natals, Inc. d/b/a Ritual (Delaware)
  • Plaintiff's Counsel: Farnan LLP; Folio Law Group PLLC
• Case Identification: 1:26-cv-00823, D. Del., 07/08/2026
• Venue Allegations: Venue is asserted on the basis that Defendant is a Delaware corporation and therefore resides in the District of Delaware.
• Core Dispute: Plaintiff alleges that Defendant's capsule-in-capsule nutritional supplements infringe a patent related to multi-compartment capsular delivery systems.
• Technical Context: The technology involves methods for delivering multiple, often incompatible, active ingredients (such as oils and solids) within a single oral-dosage capsule.
• Key Procedural History: The complaint notes that the asserted patent was the subject of a supplemental examination where the U.S. Patent and Trademark Office concluded in October 2025 that prior art did not raise a substantial new question of patentability for certain claims. The complaint also alleges pre-suit meetings and correspondence between the parties regarding the patented technology, which form the basis for a willfulness claim. The patent expired on June 11, 2026, limiting the action to a claim for past damages.

Case Timeline

Date	Event
2002-04-10	'612 Patent Priority Date
2010-03-02	'612 Patent Issue Date
2016-08-16	Alleged pre-suit meeting between Ritual and InnerCap
2025-10-15	Request for supplemental examination of the '612 Patent filed
2025-10-31	USPTO decision on supplemental examination
2025-12-14	Alleged date of cease-and-desist letter to Ritual
2026-06-11	'612 Patent Expiration Date
2026-07-08	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,670,612 - "Multi-phase, multi-compartment capsular delivery apparatus and methods for using same,"

• Patent Identification: U.S. Patent No. 7,670,612, "Multi-phase, multi-compartment capsular delivery apparatus and methods for using same," issued March 2, 2010 (the "'612 Patent").

The Invention Explained

• Problem Addressed: The patent background describes the difficulty of combining multiple active ingredients into a single capsule when those ingredients are chemically incompatible, exist in different physical states (e.g., solid vs. liquid), or require different release profiles for optimal efficacy Compl. ¶13 '612 Patent, col. 5:5-14 Combining such ingredients can lead to degradation, reduced potency, or unintended interactions Compl. ¶13 '612 Patent, col. 5:21-39
• The Patented Solution: The '612 Patent discloses a multi-compartment, capsule-in-capsule system to physically separate incompatible ingredients within a single dosage form Compl. ¶13 '612 Patent, abstract As illustrated in patent figures, a smaller, secondary capsule containing one type of ingredient can be placed inside a larger, primary capsule containing a different ingredient, often in a different physical state (e.g., a solid-filled capsule within a liquid-filled capsule) '612 Patent, Fig. 2 '612 Patent, col. 10:49-54 This separation allows for the formulation of combination products that would otherwise be unstable and enables staged release of the different ingredients Compl. ¶13
• Technical Importance: This technology enables the creation of complex, multi-ingredient supplements and pharmaceuticals in a single dosage form, which can improve stability, bioavailability, and patient compliance by reducing the number of pills a person needs to take Compl. ¶13 '612 Patent, col. 7:1-8

Key Claims at a Glance

• The complaint asserts infringement of at least claim 33, which it presents as representative, and also alleges infringement of claims 5, 6, 9, 10, 24, and 65 Compl. ¶21 Compl. ¶61
• Independent Claim 33 requires:
  • A multi-compartment capsule, comprising:
  • A first receiving chamber with at least one oil in immediate release form;
  • A second receiving chamber that (i) contains only solid ingredients, (ii) includes at least one solid active ingredient, and (iii) is formulated for time-delayed dissolution and release;
  • The ingredients in the first and second chambers are different from each other;
  • The second chamber is enveloped by the first chamber; and
  • The multi-compartment capsule is a hard shell capsule.

III. The Accused Instrumentality

Product Identification

• The complaint identifies the "Accused Products" as various capsule-in-capsule supplements, including Ritual Essential for Women Prenatal Multivitamins, Ritual Essential for Women Postnatal Multivitamins, and Ritual HyaCera Daily Skin Hydration Dietary Supplement Compl. ¶3 The infringement analysis focuses on the Ritual Essential for Women Prenatal Multivitamin product as representative of the others Compl. ¶24

Functionality and Market Context

• The Accused Products are described as having a nested, capsule-in-capsule structure Compl. ¶45 The complaint alleges the outer capsule contains an oil-based ingredient (e.g., omega-3 DHA) for immediate release, while an inner capsule contains various active ingredients in a solid, powdered state (e.g., folate, iron) and is designed for delayed release Compl. ¶¶32, 42, 45 Marketing materials provided in the complaint describe this as a "patented" "delayed-release" design intended for "optimal absorption" by dissolving in the small intestine Compl. p. 7, Fig. 1 The design physically separates oil-soluble ingredients in the outer chamber from water-soluble ingredients in the inner chamber Compl. ¶51 An image in the complaint from product literature shows the supplement facts, with colored boxes added by the plaintiff to distinguish ingredients allegedly contained in the outer oil capsule from those in the inner solid capsule Compl. p. 12, Fig. 5

IV. Analysis of Infringement Allegations

'612 Patent Infringement Allegations

Claim Element (from Independent Claim 33)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
[Preamble] A multi-compartment capsule, comprising:	The Accused Product is a multi-compartment capsule with a nested capsule-in-capsule structure. An image of the product shows an inner capsule within an outer capsule.	¶29	col. 11:18-23
[33.a] a first receiving chamber comprising at least one oil in immediate release form; and	The outer capsule serves as the first chamber and contains omega-3 DHA, an active ingredient in an oil form suitable for immediate release.	¶¶31-32	col. 10:35-44
[33.b] a second receiving chamber...	The inner capsule serves as the second chamber. An image in the complaint explicitly labels the inner and outer structures as first and second receiving chambers.	¶35	col. 10:30-34
[33.b.1] containing only solid ingredients and	The inner chamber contains ingredients in a "dry powder internal fill state," confirmed by marketing materials describing the interaction of the oil with "powder ingredients of the inner capsule."	¶¶38-39	col. 10:35-44
[33.b.2] comprising at least one active ingredient in a solid state and	The inner chamber contains active ingredients in solid form, including folate (vitamin B9), vitamin B12, and biotin.	¶42	col. 10:35-44
[33.b.3] formulated in a manner allowing for a time-delayed dissolution and release of said solid active ingredient,	The inner capsule is described as a "delayed-release" capsule. Its placement inside the outer capsule is alleged to allow for time-delayed dissolution after the outer capsule begins to dissolve.	¶¶45-47	col. 14:7-11
[33.c] wherein the ingredients contained in said first receiving chamber are different from the ingredients of said second receiving chamber,	The outer chamber contains oil-soluble ingredients (e.g., omega-3 DHA, vitamin D), while the inner chamber contains different, water-soluble ingredients (e.g., folate, iron).	¶¶50-51	col. 7:56-62
[33.d] and wherein said second receiving chamber is enveloped by said first receiving chamber,	The product has a "capsule-within-a-capsule design" where the inner capsule is contained within the outer capsule. An image shows the inner capsule fully contained within the outer capsule.	¶¶54-55	col. 10:49-54
[33.e] and wherein the multi-compartment capsule is a hard shell capsule.	The outer and inner capsules are allegedly composed of hypromellose, which the complaint asserts are "hard shell capsules."	¶59	col. 2:30-34

• Identified Points of Contention:
  • Scope Questions: Claim 33 requires a "hard shell capsule". The complaint alleges the accused capsules, made of hypromellose and gellan gum, meet this limitation Compl. ¶59 A central dispute may arise over whether this modern, vegan capsule construction falls within the scope of "hard shell capsule" as the term is used in the '612 patent, which discusses traditional hard gelatin capsules in its background section '612 Patent, col. 1:35-41
  • Technical Questions: The claim requires the inner capsule to be "formulated in a manner allowing for a time-delayed dissolution". The complaint alleges this is met because the inner capsule is a "delayed-release" capsule and its placement inside the outer capsule facilitates this function Compl. ¶45 Compl. ¶47 This raises the question of whether the inner capsule's material composition itself constitutes a "formulation" for delay, or if the delay is merely an incidental property of the nested structure. The defense may argue that the formulation of the inner capsule is for standard release and that the claim requires more than passive shielding by the outer capsule.

V. Key Claim Terms for Construction

• The Term: "hard shell capsule"

  • Context and Importance: The construction of this term is critical, as a finding that the accused product is not a "hard shell capsule" would defeat the allegation of literal infringement of representative claim 33. Practitioners may focus on this term because the accused product uses modern materials (hypromellose, gellan gum) that may differ from the traditional gelatin capsules contemplated at the time of the invention.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification lists hydroxypropyl methyl-cellulose (HPMC), the primary material of the accused capsules, as a suitable material for capsule walls, suggesting the invention was not limited to just gelatin '612 Patent, col. 2:30-31 The term is not explicitly defined, which may support giving it a broader, plain-and-ordinary meaning that encompasses modern two-piece capsules.
    • Evidence for a Narrower Interpretation: The patent's background section primarily discusses "hard gelatin capsules" and contrasts them with "soft elastic capsules," potentially suggesting that "hard shell capsule" was intended to refer to the conventional technology of the time '612 Patent, col. 1:35-41 '612 Patent, col. 2:50-52

• The Term: "formulated in a manner allowing for a time-delayed dissolution"

  • Context and Importance: This term is central to whether the accused product's delayed-release mechanism infringes. The dispute will likely focus on whether the inner capsule itself is specially "formulated" for delay or if the delay is just a consequence of its physical placement.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent frequently discusses using "time-release coatings" to achieve delayed release, which is a form of formulation '612 Patent, col. 14:7-11 A broad reading could suggest that any intentional material selection or construction that results in a time delay, as opposed to immediate release, meets the "formulated in a manner" requirement.
    • Evidence for a Narrower Interpretation: The language could be interpreted to require that the inner capsule be independently capable of delayed release due to its own formulation (e.g., via a specific enteric coating), rather than relying on the shielding effect of the outer capsule. The complaint's own statement that "both the formulation... and its placement... allow for time-delayed dissolution" Compl. ¶47 could be used to argue that the "formulation" alone is not the sole cause of the delay.

VI. Other Allegations

• Willful Infringement: The complaint alleges that Ritual's infringement was willful Compl. ¶63 This allegation is based on alleged pre-suit knowledge of the '612 Patent. Specifically, the complaint states that on August 16, 2016, Ritual's Vice President of Research & Development met with the patent's inventor to discuss capsule technology and was made aware of the '612 Patent and its claims Compl. ¶¶64-67 The complaint further alleges that Ritual subsequently switched its product design to the accused infringing configuration after this meeting Compl. ¶68 Willfulness is also alleged based on Ritual's continued infringement after receiving a cease-and-desist letter on December 14, 2025 Compl. ¶70 Compl. ¶72

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of definitional scope: does the claim term "hard shell capsule", as used in the context of the '612 patent, encompass the defendant's modern capsule construction made of hypromellose and gellan gum, or is its meaning limited to the traditional gelatin-based capsules discussed in the patent's background?
• A key question of claim interpretation will be whether the inner capsule is "formulated in a manner allowing for a time-delayed dissolution". The court will need to determine if this requires the inner capsule to be independently formulated for delay (e.g., with a specific coating), or if the use of a standard capsule that is passively shielded by an outer capsule is sufficient to meet this limitation.
• An important factual question for willfulness will be what was specifically discussed at the August 2016 meeting between Ritual and InnerCap. The outcome will depend on the evidence presented regarding the extent of Ritual's knowledge of the '612 patent and its claims prior to and during the period of alleged infringement.